Maintenance: Wednesday, 22 November 2017, 07:00-08:00
Maintenance work on the ZORA servers is provided. There may be short interruptions in the service between 07:00 and 08:00. Thank you for your patience.
Cima, I; Schiess, R; Wild, P; Kaelin, M; Schüffler, P; Lange, V; Picotti, P; Ossola, R; Templeton, A; Schubert, O; Fuchs, T; Leippold, T; Wyler, S; Zehetner, J; Jochum, W; Buhmann, J M; Cerny, T; Moch, H; Gillessen, S; Aebersold, R; Krek, W (2011). Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 108(8):3342-3347.
Kälin, M; Cima, I; Schiess, R; Fankhauser, N; Powles, T; Wild, P; Templeton, A; Cerny, T; Aebersold, R; Krek, W; Gillessen, S (2011). Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. European Urology, 60(6):1235-1243.
Martinelli, G; Schmitz, S F H; Utiger, U; Cerny, T; Hess, U; Bassi, S; Okkinga, E; Stupp, R; Stahel, R; Heizmann, M; Vorobiof, D; Lohri, A; Dietrich, P Y; Zucca, E; Ghielmini, M (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28(29):4480-4484.
Strasser, F; Lutz, T A; Maeder, M T; Thuerlimann, B; Bueche, D; Tschöp, M; Kaufmann, K; Holst, B; Brändle, M; von Moos, R; Demmer, R; Cerny, T (2008). Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer, 98:300-308.